Olbina G, Cieslak D, Ruzdijic S, Esler C, An Z, Wang X, Hoffman R, Seifert W, Pietrzkowski Z
Research Department, ICN Pharmaceuticals, Inc., Costa Mesa, CA 92626, USA.
Anticancer Res. 1996 Nov-Dec;16(6B):3525-30.
We examined the importance of IL-8 receptor B mRNA expression in the growth of non-small cell lung cancer (NSCLC). Using antisense oligonucleotide ICN 197, we were able to inhibit IL-8 R B mRNA expression in vitro. The sequence specific effect of antisense oligonucleotide and down-regulation of IL-8 R B mRNA was shown by Reverse Transcription Polymerase Chain Reaction (RT-PCR) and Southern blot analysis. The proliferation of treated cells was measured by 3H thymidine incorporation. We found that treatment of NSCLC cells caused reversible growth inhibition and reversible down regulation of IL-8 R B mRNA. Furthermore, we observed that the treatment of nude mice with oligonucleotide ICN 197 inhibited the growth of tumors developed from NSCLC cells injected subcutaneously. Our data in vitro suggest that IL-8 receptor B mRNA expression is required to maintain the proliferative rate of NSCLC. Based on the data in vivo. oligonucleotide ICN 197 may be considered for the development of novel therapeutic treatment for lung cancer.
我们研究了白细胞介素-8受体B(IL-8 receptor B)信使核糖核酸(mRNA)表达在非小细胞肺癌(NSCLC)生长中的重要性。使用反义寡核苷酸ICN 197,我们能够在体外抑制IL-8 R B mRNA的表达。通过逆转录聚合酶链反应(RT-PCR)和Southern印迹分析显示了反义寡核苷酸的序列特异性效应以及IL-8 R B mRNA的下调。通过3H胸腺嘧啶核苷掺入法测量处理后细胞的增殖。我们发现,对NSCLC细胞的处理导致可逆的生长抑制和IL-8 R B mRNA的可逆下调。此外,我们观察到用寡核苷酸ICN 197处理裸鼠可抑制皮下注射NSCLC细胞所形成肿瘤的生长。我们的体外数据表明,IL-8受体B mRNA表达是维持NSCLC增殖率所必需的。基于体内数据,寡核苷酸ICN 197可考虑用于开发肺癌的新型治疗方法。